Germany joins CARB-X partnership in the fight against deadly drug-resistant superbugs
CARB-X announced today it has signed a partnership agreement with Germany’s Federal Ministry of Education and Research (BMBF) to invest €39 million over four years in the early development of antibiotics, vaccines, and diagnostics to combat drug-resistant bacteria. Under the agreement, BMBF will also provide an additional €1 million in direct support to a consortium of the German Center for Infection Research (DZIF), the Federal Institute for Vaccines and Biomedicines (PEI) and the Federal Institute for Drugs and Medical Devices (BfArM), which is joining the CARB-X Global Accelerator Network, a network of 10 accelerators around the world to support CARB-X funded projects. CARB-X is a global non-profit partnership housed at Boston University.
Article: CARB-XSmart Innovations